Summary & Overview
HCPCS C9035: Injection of Aripiprazole Lauroxil (Aristada Initio), 1 mg
HCPCS Level II code C9035 denotes the injection of aripiprazole lauroxil (Aristada Initio), 1 mg, used to initiate long-acting antipsychotic therapy. Nationally, such initiation-dose codes matter because they capture the administration of specialty medications in outpatient and behavioral health settings and affect coverage, prior authorization, and site-of-care billing practices.
Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise clinical context for the medication and service, an overview of typical sites of service where the injection is delivered, and what the code represents for billing workflows. The publication outlines common benchmarking topics and policy touchpoints relevant to this service line, including payer coverage considerations, billing placement on the claim, and how initiation-dose codes relate to ongoing maintenance therapy.
This summary provides practical reference points for revenue cycle and clinical teams seeking to align documentation and claim submission with national payer expectations, while presenting the clinical framing of an initiation injection for long-acting antipsychotic treatment.
Billing Code Overview
HCPCS Level II code C9035 describes an injection of aripiprazole lauroxil (Aristada Initio), 1 mg. This code represents a medication administration service for initiating long-acting injectable antipsychotic therapy using the Aristada Initio formulation, which is employed to rapidly establish therapeutic levels of aripiprazole prior to maintenance dosing.
Service type: Medication injection / initiation dose for long-acting antipsychotic therapy
Typical site of service: Outpatient clinic, psychiatric clinic, behavioral health center, or other ambulatory care settings where injectable antipsychotic initiation is administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 28-year-old patient with a diagnosis of schizophrenia or schizoaffective disorder presents for initiation of long‑acting injectable antipsychotic therapy. The clinician elects to administer an initiation dose of aripiprazole lauroxil using the proprietary initiation formulation C9035 (aripiprazole lauroxil [aristada initio], reported per 1 mg). The clinical workflow includes: review of prior antipsychotic history and baseline mental status, confirmation of current medications and potential interactions, assessment of injection site and contraindications, informed consent, preparation of the product per manufacturer guidance, administration via intramuscular injection (typically into the deltoid or gluteal muscle), observation for immediate adverse reactions for 15–30 minutes, documentation of lot number and dose in the medical record, scheduling of follow‑up maintenance injections (eg, standard aripiprazole lauroxil dosing at recommended intervals), and coordination with pharmacy for any required prescription and billing. Typical sites of service for this initiation injection include outpatient behavioral health clinics, psychiatric outpatient offices, community mental health centers, and outpatient infusion/injection clinics. Typical patient scenario: adult with inadequate adherence to oral antipsychotic therapy or requiring rapid initiation of therapeutic plasma levels prior to transitioning to the maintenance long‑acting injectable formulation.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the day of procedure |